USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: L2 DIAGNOSTICS, LLC
City: NEW HAVEN
State: CT
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $5,508,600.00 22
SBIR Phase II $3,828,838.00 5
STTR Phase I $4,605,802.00 16
STTR Phase II $5,079,557.00 5

Award List:

VACCINATION AGAINST HOOKWORM WITH RECOMBINANT ANTIGENS

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Raymond A. Koski
Award Amount: $149,657.00
Abstract:
Not Available Chemical weapons are highly lethal, inexpensive weapons of mass destruction. Present methods for detection of exposure to sulfur mustard are expensive and time-consuming. Accordingly, there is an urgent need for the development of rapid, simple, and reliable detection methods… More

OSPA NEGATIVE ELISA FOR LYME DISEASE

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Raymond A. Koski
Award Amount: $99,303.00
Abstract:
Not Available The objective of the overall SBIR effort is to design, demonstrate, and deliver to the AF a gaseous flow reactor capable of producing high-density flows of critical chemical species. Depending upon the results of a detailed flow analysis the reactor would be designed to support either… More

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Raymond A. Koski
Award Amount: $365,729.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Raymond A. Koski
Award Amount: $0.00

Vaccination Against West Nile Virus

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Raymond A. Koski
Award Amount: $99,529.00
Abstract:
A commercially viable vaccine for the prevention of West Nile virus infection is the overall objective of this project. West Nile virus was isolated for the first time in the Western hemisphere in 1999, when seven New York patients died as a result of a West Nile virus outbreak. The virus is still… More

Vaccination Against Ixodes scapularis Tick Bites

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Raymond A. Koski
Award Amount: $99,562.00
Abstract:
Lyme disease is a multi-systemic infection and is caused by the pathogen Borrelia burgdorferi. The blacklegged tick, Ixodes scapularis, is the common vector for B. burgdorferi. The purpose of this project is to develop an anti-I. scapularis vaccine to block tick attachment and tick-mediated disease… More

VACCINATION AGAINST IXODES SCAPULARIS TICK BITES

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michel Ledizet
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): Lyme disease is a multi-systemic infection caused by the pathogen Borrelia burgdorjeri. The black-legged tick, Ixodes scapularis, is the common vector for B. burgdorferi. This tick also transmits the agents of human granulocytic ehrlichiosis and babesiosis. The… More

VACCINATION AGAINST IXODES SCAPULARIS TICK BITES

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: Michel Ledizet
Award Amount: $748,024.00
Abstract:
DESCRIPTION (provided by applicant): Lyme disease is a multi-systemic infection caused by the pathogen Borrelia burgdorjeri. The black-legged tick, Ixodes scapularis, is the common vector for B. burgdorferi. This tick also transmits the agents of human granulocytic ehrlichiosis and babesiosis. The… More

Therapeutic Activity of a Novel Tick Immunosuppressant

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michel E. Ledizet
Award Amount: $99,728.00
Abstract:
DESCRIPTION (provided by applicant): The overall objective of this proposal is to evaluate the therapeutic potential of a novel immunosuppressant protein produced by tick salivary glands. Ixodes scapularis, the black-legged tick, circumvents the host's immune response by multiple mechanisms as it… More

A novel platelet inhibitor from bloodfeeding hookworms

Award Year / Program / Phase: 2003 / STTR / Phase I
Agency: HHS
Research Institution: YALE UNIVERSITY
Principal Investigator: Michael Cappello
Award Amount: $99,383.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Thromboembolic disease is a major cause of morbidity and mortality in the developed world. Because platelets play a critical role in the activation and propagation of thrombosis, they represent important targets for new anti-thrombotic drugs. A potent… More

A Novel Family of Anticoagulants from Ixodes scapularis

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michel E. Ledizet
Award Amount: $138,854.00
Abstract:
DESCRIPTION (provided by applicant): The overall objective of this proposal is to evaluate the anticoagulant properties of a family of novel tick salivary proteins Ixodes scapularis, the black-legged tick, circumvents host hemostatic mechanisms as it engorges on vertebrate hosts. This tick's saliva… More

Vaccination Against West Nile Virus

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: Raymond A. Koski
Award Amount: $729,355.00
Abstract:
DESCRIPTION (provided by applicant): A commercially viable recombinant subunit vaccine to prevent West Nile virus infection is the overall objective of this project. West Nile virus was isolated for the first time in North America in 1999. In less than three years, the geographical distribution of… More

Vaccination Against West Nile Virus

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Raymond A. Koski
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): A commercially viable recombinant subunit vaccine to prevent West Nile virus infection is the overall objective of this project. West Nile virus was isolated for the first time in North America in 1999. In less than three years, the geographical distribution of… More

Antibody Prophylaxis and Therapy of Flavivirus Infection

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Raymond A. Koski
Award Amount: $969,452.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to develop antibody therapy and prophylaxis to treat and prevent life-threatening flavivirus infections. West Nile virus is the focus of Phase I studies. Our working hypothesis is that high titer anti-envelope protein… More

Small Molecule Alanine Racemase Inhibitors as Novel Therapeutics for Tuberculosis

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Karen G. Anthony
Award Amount: $169,964.00
Abstract:
DESCRIPTION (provided by applicant): Once thought to be on the decline, tuberculosis (TB) still remains a major global health problem today. With an estimated eight million new cases and two million deaths annually, TB is the leading cause of death from an infectious disease. This situation is… More

Small Molecule West Nile Virus Inhibitors

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $200,994.00
Abstract:
DESCRIPTION (provided by applicant): Due to its high prevalence and its ability to cause severe disease in humans for which treatments are unavailable, West Nile (WN) virus has become an important public health concern in the U.S. The unmet medical need of developing effective WN virus therapeutics… More

Glioma Therapeutics Targeting Glioma Pathogenesis-related Protein

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $219,461.00
Abstract:
DESCRIPTION (provided by applicant): Gliomas are malignant tumors that arise from glial cells in the central nervous system and are among the deadliest of human cancers. These tumors are notorious for their aggressive and highly invasive behavior. Their ab ility to invade into the surrounding normal… More

Nanoparticle-based vaccines against flaviviruses

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $591,408.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this proposal is to develop nanoparticle-based vaccines against West Nile virus. West Nile virus is an emerging human pathogen and a model for other medically important flaviviruses such as dengue viru s. We and others have shown that a… More

Lyme Disease Diagnostics Using In Vivo Expressed Borrelia Burgdorferi Antigens

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $275,834.00
Abstract:
DESCRIPTION (provided by applicant): Lyme disease, due to infection with the Ixodes tick-transmitted spirochete Borrelia burgdorferi, is the most common vector-borne disease in the United States, with over 20,000 cases reported to the CDC annually. After d eposition in the skin, spirochetes can… More

Tick Midgut Thrombin Inhibitor as a Vaccine Target

Award Year / Program / Phase: 2008 / STTR / Phase I
Agency: HHS
Research Institution: N/A
Principal Investigator:
Award Amount: $213,408.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): We seek in this proposal to develop a tick vaccine to block tick feeding and pathogen transmission to the vertebrate host. Ticks can harbor bacterial, viral and protozoan pathogens and infected ticks transmit pathogens to the mammalian host during feeding,… More

New Serodiagnostics for Isocyanate Exposure, A Major Cause of Occupational Asthma

Award Year / Program / Phase: 2008 / STTR / Phase I
Agency: HHS
Research Institution: N/A
Principal Investigator:
Award Amount: $202,698.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Occupational exposures are estimated to account for 9-15% of adult asthma cases. Among the most common causes of occupational asthma are isocyanates, reactive chemicals necessary to make polyurethane products (construct ion, automotive, military, medical, foam,… More

Therapeutic Inhibition of MIF in Rheumatoid Arthritis

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Karen G. Anthony
Award Amount: $239,686.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is a small molecule therapeutic of benefit to patients with rheumatoid arthritis (RA), which will act by reducing the inflammatory response triggered by macrophage migration inhibitor y factor (MIF). RA afflicts up to 4 million… More

A serologic assay to measure successful Lyme borreliosis antibiotic therapy

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michel Ledizet
Award Amount: $278,455.00
Abstract:
DESCRIPTION (provided by applicant): Lyme disease, due to infection with the Ixodes tick-transmitted spirochete Borrelia burgdorferi, is the most common vector-borne disease in the United States, with over 20,000 cases reported to the CDC annually. There i s controversy over the length of antibiotic… More

Bio-monitoring Methylene Diphenyl Diisocyanate (MDI) exposure and body burden

Award Year / Program / Phase: 2010 / STTR / Phase I
Agency: HHS
Research Institution: Yale University
Principal Investigator: Adam Wisnewski – 203-737-2544
Award Amount: $211,466.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Exposure to isocyanate, the essential cross-linker for making polyurethane, is a leading cause of occupational asthma world-wide. Three major types of isocyanate are used commercially, methylene-diphenyl diisocyanate (MDI) and toluene diisocyanate (TDI), or… More

EGFR Peptides as Vaccines in Anti-Tumor Immunity

Award Year / Program / Phase: 2010 / STTR / Phase II
Agency: HHS
Research Institution: Yale University
Principal Investigator: Mark J. Mamula – 203-737-2840
Award Amount: $1,118,129.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Epidermal Growth Factor Receptor (EGFR) bearing tumors remain as one of the most insidious and difficult to treat human malignancies, affecting thousands of individuals each year. Our proposed studies are aimed at developing novel tumor immunotherapy by using… More

A nanoparticle-based vaccine against leishmaniasis

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: YALE UNIVERSITY
Principal Investigator: Diane Mcmahon pratt – 203-785-4481
Award Amount: $599,977.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a recombinant subunit vaccine against cutaneous leishmaniasis. This vaccine will incorporate two protein antigens, TSA/TryP and P-4. Both antigens are highly conserved among Leishmania species, arerecognized by T cells of human patients, and… More

T cell cytokine assay for the diagnosis of disseminated Lyme borreliosis

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: YALE UNIVERSITY
Principal Investigator: Linda K. Bockenstedt – 203-785-3893
Award Amount: $281,029.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Lyme disease, due to infection with the Ixodes tick-transmitted spirochete Borrelia burgdorferi, is the most common vector-borne disease in the United States, with more than 28,000 cases reported annually. The infectioncan remain localized to the skin or… More

Diagnostic tools to link Bacteroides fragilis toxin isotypes and human disease

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Saraspadee Mootien – 203-393-9439
Award Amount: $573,352.00
Abstract:
DESCRIPTION (provided by applicant): The goal of the proposed research is to develop a series of diagnostic assays that will detect specific types of enterotoxigenic Bacteroides fragilis (ETBF). ETBF has been shown to cause diarrhea as well as bowel inflammation and colitis. Experimental evidence… More

Bio-monitoring Methylene Diphenyl Diisocyanate (MDI) exposure and body burden

Award Year / Program / Phase: 2011 / STTR / Phase II
Agency: HHS
Research Institution: YALE UNIVERSITY
Principal Investigator: Adam Wisnewski – (203) 737-2544
Award Amount: $1,356,039.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Exposure to isocyanate, the essential cross-linker for making polyurethane, is a leading cause of occupational asthma world-wide. Three major types of isocyanate are used commercially, methylene-diphenyl diisocyanate (MDI) and toluene diisocyanate (TDI), or… More

Therapeutic Inhibition of MIF in Rheumatoid Arthritis

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Karen G. Anthony – 203-503-0383
Award Amount: $988,799.00
Abstract:
DESCRIPTION (provided by applicant): The long-term product goal of this project is a small molecule therapeutic to treat rheumatoid arthritis (RA), which acts by reducing the inflammatory response triggered by the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF). Since MIF is… More

Measurement of Beta Cell Death in Diabetes

Award Year / Program / Phase: 2012 / STTR / Phase I
Agency: HHS
Research Institution: YALE UNIVERSITY
Principal Investigator: Kevan C. Herold – 203-785-6507
Award Amount: $284,931.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): All forms of diabetes are characterized by the death of insulin producing cells. In Type 1 diabetes (T1D), this leads to the reliance on exogenous insulin for survival. In addition, there is cell loss in T2D and inindividuals who lose islet or pancreas… More

Small Molecule Antiviral Agents Against Flaviviruses

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: Michel Ledizet, PI/Senior Scientist – (203) 503-0383
Award Amount: $149,404.00
Abstract:
Flaviviruses enter mammalian cells by a mechanism involving a structural rearrangement of the stem region of their envelope protein. The stem region establishes specific molecular contacts with amino acid residues of domain II of the rest of the envelope protein. Our hypothesis is that tetrapeptides… More

Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michel Ledizet – 203-737-2596
Award Amount: $290,340.00
Abstract:
DESCRIPTION (provided by applicant): Lyme disease, due to infection with the Ixodes tick-transmitted spirochete Borrelia burgdorferi, is the most common vector-borne disease in the United States, with over 38,000 confirmed and probable cases reported to the CDC in 2009. Spirochetes first establish… More

Triplex-mediated DNA repair as a novel therapy for Hurler Syndrome patients

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elizabeth Peterson-roth – 203-503-0383
Award Amount: $268,211.00
Abstract:
DESCRIPTION (provided by applicant): This is a proposal to test the feasibility of using triplex molecules for use as a therapeutic to correct Hurler Syndrome (HS). Lysosomal storage diseases (LSDs), such as HS, represent a diverse collection of monogenicdisorders that have devastating clinical… More

Small Molecule Antiviral Agents Against Flaviviruses

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: DOD
Principal Investigator: Michel Ledizet, Senior Research Scientist – (203) 503-0383
Award Amount: $996,931.00
Abstract:
Flaviviruses, and dengue viruses in particular, are significant human pathogens. No vaccine or specific therapeutic agent is available against West Nile and dengue viruses. Our goal is to develop peptide-derived therapeutics active against West Nile virus, dengue viruses, and other flaviviruses. … More

A Lyme disease vaccine using newly identified in-vivo expressed antigens

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michel Ledizet – 203-503-0383
Award Amount: $595,406.00
Abstract:
DESCRIPTION (provided by applicant): Lyme disease is the most common arthropod-borne disease in the United States, with over 38,000 confirmed and probable cases reported in 2009. The causative agent of Lyme disease is the spirochete Borrelia burgdorferi, which is transmitted by the tick of the… More